Treatment of isolated growth hormone deficiency type IA due to GH-I gene deletion with recombinant human insulin-like growth factor I.
Biosynthetic insulin-like growth factor I (IGF-I) was administered subcutaneously twice a day for one year to a patient with isolated growth hormone deficiency (IGHD) type IA with high titres of anti-GH antibody (up to 1:1,000,000). During IGF-I therapy he showed good linear growth without any side effects, such as hypoglycemia and anti-IGF-I antibody formation. Administration of IGF-I to IGHD type IA with poor response to GH therapy appears to have a beneficial effect on growth.
Nishi
Y
Y
Department of Pediatrics, Hiroshima Red Cross Hospital, Japan.
Hamamoto
K
K
Kajiyama
M
M
Fujiwara
M
M
Miyagawa
S
S
Hasegawa
Y
Y
Hasegawa
T
T
D000906:Antibodies / Q000097:blood; D002352:Carrier Proteins / Q000097:blood; D002675:Child, Preschool; D004393:Dwarfism, Pituitary / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D017353:Gene Deletion; D013006:Growth Hormone / Q000172:deficiency* / Q000235:genetics*; D006131:Growth Inhibitors / Q000097:blood; D006801:Humans; D007279:Injections, Subcutaneous; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000096:biosynthesis; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000096:biosynthesis
D000906:Antibodies; D002352:Carrier Proteins; D006131:Growth Inhibitors; D018969:Insulin-Like Growth Factor Binding Proteins; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone